DCLK1 and cancer: Because the COX2/PGE2 pathway is one of the key inflammatory mediators that sculpt the tumor-promoting microenvironment 65, 66, recent studies revealed that the inhibition of DCLK1 kinase activity significantly increases T cell-mediated anti-cancer immunity, but a definitive molecular mechanism has not been identified 67, 68.